<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01713842</url>
  </required_header>
  <id_info>
    <org_study_id>RB 11-075 TENOR</org_study_id>
    <nct_id>NCT01713842</nct_id>
  </id_info>
  <brief_title>Tocilizumab Effect iN pOlymyalgia Rheumatica</brief_title>
  <acronym>TENOR</acronym>
  <official_title>Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1:&#xD;
&#xD;
      Patients are treated with infusions of Tocilizumab (TCZ) for 3 months. Clinical evaluation is&#xD;
      performed using PMR-AS.&#xD;
&#xD;
      The PMR-AS is computed by summing the 5 variables after multiplying by 0.1 for weighting&#xD;
      purposes: PMR-AS (activity scale = AS) = C reactive protein (CRP) (mg/dl) + patient scale&#xD;
      (VASp) (0-10 scale) + physician scale (VASph) (0-10 scale) + morning stiffness(MST)&#xD;
      [min]×0.1) + elevation of upper limbs (EUL) (0-3 scale).&#xD;
&#xD;
      At the end of the phase 1,the patients stop TCZ and entered in phase 2 at week 12.&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
      All the patients are included in the phase 2 and treated with glucocorticoid (GC)for 3&#xD;
      months. Two arms are possible according to the PMR-AS. Either the classical GC treatment&#xD;
      (0.3mg/kg), either a low dose group of GC(0.15mg/kg) .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy at W12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>PMR-AS at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and efficacy during the study</measure>
    <time_frame>Week 2,4,8,12,16,20 and 24</time_frame>
    <description>To maintain low disease activity (PMR-AS) in the low corticosteroid dose group from W12 to W24&#xD;
On the inflammatory changes (synovitis, myositis, tenosynovitis aund bursitis) between baseline, W2 and 12 visualize by ultrasonography, MRI and Tep-Scan.&#xD;
On sparing corticosteroid, with the comparison of the cumulative corticosteroid dosage beetwen the two groups of patients in the phase 2, W12 to 24.&#xD;
On the circulating serum cytokines and immunoregulators (IL-6, IL-1, BLyS/BAFF, IL-6 receptor, gp130) and B cells receptors and on the phenotype of circulating T- and B-cells between baseline and W4 and 12 On inflammatory parameters (CRP and ESR) between baseline and W 2,4,8,12,16,20 and 24&#xD;
On the quality of life of patients between baseline and W 4,12,16, 20 and 24&#xD;
To evaluate the side-effects in relation to the use of Tocilizumab treatment. [ Time Frame: After first, second and third treatment and during follow up ]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Polymyalgia Rheumatica</condition>
  <arm_group>
    <arm_group_label>TCZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCZ</intervention_name>
    <description>Tocilizumab at week 0, 4 and 8.</description>
    <arm_group_label>TCZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 50 years and 75 years included&#xD;
&#xD;
          -  PMR-AS &gt; 10&#xD;
&#xD;
          -  PMR according to the Chuang criteria&#xD;
&#xD;
          -  Evolving since less than 12 months&#xD;
&#xD;
          -  Without Horton disease&#xD;
&#xD;
          -  Able to understand and accept the study&#xD;
&#xD;
          -  Agree to sign the inform consent form&#xD;
&#xD;
          -  Without GC, or at least during 1 month and stop since 7 days before the inclusion.&#xD;
&#xD;
          -  Stable dose of Nonsteroidal anti-inflammatory since 4 weeks before the inclusion.&#xD;
&#xD;
          -  Birth controlled during all the study and 6 months after&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disagree to participated&#xD;
&#xD;
          -  Unable to understand the study&#xD;
&#xD;
          -  Participation to an other study in the 3 months before the inclusion&#xD;
&#xD;
          -  Treated by GC at 0.3mg/kg/d in the past 7 days&#xD;
&#xD;
          -  Less than 50 years old or more than 75 years old&#xD;
&#xD;
          -  Uncontrolled dyslipidemia, high blood pressure or cardiovascular disease&#xD;
&#xD;
          -  Histories of important allergy&#xD;
&#xD;
          -  Historically positive test or test positive at screening for HIV-1 antibody, hepatitis&#xD;
             B surface antigen, or hepatitis C antibody.&#xD;
&#xD;
          -  Abnormal screening blood test : leukocyte count less than 3.5 × 109 cells/L,&#xD;
             neutrophil count less than 2 × 109 cells/L, hemoglobin level less than 85 g/L,&#xD;
             platelet count less than 100 × 109 cells/L, or hepatic aminotransferase or alkaline&#xD;
             phosphatase levels greater than 3 times the upper limit of normal&#xD;
&#xD;
          -  Other inflammatory rheumatic disease or connective disease&#xD;
&#xD;
          -  Clinical evidence of significant unstable or uncontrolled acute or chronic diseases&#xD;
             not due to PMR (eg. Cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic,&#xD;
             renal, neurological, malignancy or infectious diseases)&#xD;
&#xD;
          -  Current drug or alcohol abuse&#xD;
&#xD;
          -  Patients treated with an immunosuppressive agents in the past 4 weeks&#xD;
&#xD;
          -  Live/attenuated vaccine in the past 4 weeks&#xD;
&#xD;
          -  Clinical symptoms of giant cell arteritis&#xD;
&#xD;
          -  History of infection or infestation in the past 3 months&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Planned surgical procedure&#xD;
&#xD;
          -  History of malignant neoplasm within the last 5 years, except for adequately treated&#xD;
             cancer of the skin (basal or squamous cell)&#xD;
&#xD;
          -  History or current tumoral hematological disease&#xD;
&#xD;
          -  Severe allergic or anaphylactic reactions about one of the TCZ component&#xD;
&#xD;
          -  Pregnant women during the study and six month after the end of the study&#xD;
&#xD;
          -  Breast feeding mother&#xD;
&#xD;
          -  Dysthyroidia&#xD;
&#xD;
          -  Unstable treatment by statin in the past 3 months&#xD;
&#xD;
          -  Parkinson disease&#xD;
&#xD;
          -  Fibromyalgia&#xD;
&#xD;
          -  Peripheric arthritis&#xD;
&#xD;
          -  Articular chondrocalcinosis or hydorxyapatites rhumatisms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie DEVAUCHELLE, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>September 17, 2012</study_first_submitted>
  <study_first_submitted_qc>October 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2012</study_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tocilizumab</keyword>
  <keyword>Polymyalgia Rheumatica</keyword>
  <keyword>Glucocorticotherapy</keyword>
  <keyword>PMR-AS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

